Articles tagged with Vaccine Development
A research team developed a vaccine targeting synthetic opioid fentanyl to block its entry into the brain, preventing fatal effects. The breakthrough could have major implications for treating Opioid Use Disorder, with potential relapse prevention capabilities.
Researchers discovered Mycoplasma pneumoniae's lipids spur T cells to overproduce IL-17, leading to neutrophil recruitment and vaccine-enhanced disease. B cells also play a role in modulating the immune response, suggesting they may hold disease in check.
Researchers identified specific monkeypox mutations that contribute to its continued infectiousness. The virus is accumulating mutations where drugs and antibodies from vaccines are supposed to bind, making it smarter and more infectious.
A comprehensive review and meta-analysis found that young adults under 40 have a slightly elevated risk for myocarditis or pericarditis after mRNA COVID-19 vaccination. The analysis analyzed data from over 58 million participants and explored the relationship between COVID-19 vaccine and these rare but dangerous adverse reactions.
A new study led by Duke-NUS Medical School scientists found that inactivated SARS-CoV-2 vaccines elicit a broad immune response against different proteins on the virus, while mRNA vaccines stimulate a single spike protein response. This broader T-cell response may be beneficial in preventing severe COVID-19 disease.
A study published in The BMJ found a small increased risk of thrombosis with thrombocytopenia syndrome (TTS) after vaccination against the Covid-19 virus, particularly with adenovirus vaccines. Researchers recommend considering these risks when planning future immunization campaigns and vaccine development.
Researchers have developed an intranasal COVID-19 vaccine that works against the original virus and two variants, including omicron, in hamsters. The vaccine stimulates a strong immune response both systemically and in the respiratory tract.
A new study by the University of Waterloo found that individuals with anxiety disorders are not more hesitant to get vaccinated than those without. Instead, discomfort with uncertainty is a significant predictor of vaccine hesitancy in both anxious and non-anxious individuals.
Researchers developed a groundbreaking model to estimate bait vaccination effectiveness in wild animals by analyzing the proportion of immunized animals and vaccine applications. The study successfully tested the model using real data from Japan's CSF outbreak, demonstrating a measurable increase in immunized wild boars.
Two nonprofit research organizations partner to create new TB vaccine candidates with diverse adjuvant technologies and genetically diverse mouse models. The team aims to develop thermostable vaccines that can last for several months at room temperature or years in standard refrigerators.
A study of Russian adults found that those who accept vaccination unconditionaly are more likely to have higher trust in government and less frequent social media use. In contrast, vaccine rejectors tend to be more extroverted and friendly but less trusting of institutions.
Babies born during the pandemic were less likely to meet social communication developmental milestones, such as expressing a word or pointing, but more likely to crawl. Researchers suggest that lockdowns may have reduced language exposure and face-to-face interactions, leading to these delays.
The article highlights the need for a unified approach to prevent and respond to pandemics by adopting a One Health strategy. This involves targeted preparedness, drug and vaccine research, and worldwide cooperation on surveillance and stopping disease spread.
A novel COVID-19 vaccine developed by Brazilian scientists combines two SARS-CoV-2 proteins to trigger a cellular immune response. The vaccine, called SpiN, showed promise in animal trials, protecting against three strains of the virus and reducing viral load by up to 50 times.
A Rutgers-led study statistically evaluated government data to determine if COVID-19 vaccination increases the incidence of Guillain-Barré syndrome. The results show no significant association between any COVID-19 vaccinations and the disease.
Researchers develop custom vaccines that induce broadly neutralizing antibodies to protect against HIV variants. The team uses a modified HIV spike protein to prime the immune system, paving the way for an effective HIV vaccine.
Researchers developed a highly effective and safe Zika vaccine technology that prevents systemic infection in pregnant mice and stimulates an immunogenic reaction. The vaccine was tested in various mouse models, proving safe and protective against the virus.
A new scoring tool prioritizes countries with higher vaccination rates and vulnerable populations, aiming to allocate Covid-19 vaccines more fairly. The tool considers a broader range of factors than current global COVAX facilities, which have been criticized for insufficient access.
A study found that the 2021/22 influenza vaccine had only 36% effectiveness against A(H3N2) in Canada, with a mismatch between the vaccine strain and the circulating virus. This suggests that the replacement of the vaccine strain for the upcoming season is necessary.
Research finds strong association between enterovirus infection and type 1 diabetes; individuals with T1D eight times more likely to have an enterovirus infection than others. Vaccines aimed at preventing enterovirus infection may help prevent T1D development.
Researchers from NAU and University of Washington collaborate to create a safe and effective vaccine for Valley Fever, a fungal infection spreading due to climate change. The project aims to address the growing threat of emerging epidemics and prevent disease through vaccination.
Researchers have developed SARS-CoV-2 virus-like particles (VLPs) that can mimic the virus's behavior, allowing for safer vaccine development and testing. These VLPs could help scientists understand how the virus invades the central nervous system and potentially lead to more effective vaccines.
A team of scientists from SMART and NTU Singapore has developed a rapid point-of-care test kit that measures antibodies against SARS-COV-2 and its variants, offering personalized vaccination strategies. The test kit requires just 10 minutes to show results and has up to 93% accuracy.
Researchers found that a 'slow delivery, escalating dose' vaccination strategy can prompt B cells to spend months mutating and evolving their antibodies, leading to more effective long-lasting vaccines. This breakthrough has implications for vaccines against pathogens like influenza, malaria, and SARS-CoV-2.
A global consortium has launched best practice surveillance protocols for Group A Streptococcus (Strep A) research, providing clear case definitions and guiding researchers in clinical trials. The new protocols aim to accelerate the development of a safe and effective Strep A vaccine.
Researchers at the University of Zurich have developed a new immunotherapy strategy to eliminate fibroblasts in targeted manner, reducing lung and liver fibrosis in mice. The treatment triggers an immune response via cytotoxic T-cells, eliminating activated connective tissue cells while leaving resting cells undamaged.
Researchers at Cleveland Clinic's FRIC found that cytoskeleton disruption is a key signal for the body to respond to viruses. This discovery has potential implications for developing new anti-viral vaccines and treatments.
Researchers have developed a malaria vaccine candidate that is safe and immunogenic in adults, offering improved protection against the disease. The vaccine combines FMP013 antigen with ALFQ adjuvant, which displays promising immune-enhancing effects.
Researchers developed an AI method to predict how well new COVID-19 variants infect human cells and evade antibodies. The system can analyze a million mutated variants, enabling the development of next-generation antibody therapies and vaccines that provide broader protection against potential future variants.
Researchers analyzed COVID-19 lockdown strategies in Germany, Israel, and the US to determine optimal policy changes based on vaccine development timelines. Lockdowns were stricter before vaccine approval and continued to intensify after approval until vaccination reached a sufficient percentage.
A new Israeli study found that myocarditis cases were rare and mild after the third dose of Pfizer-BioNTech COVID-19 vaccine, with a risk of 1 in 15,000 among young males. The study's findings suggest potential explanations for the increased risk, including medical precautions and time between doses.
Experts argue that flawed narratives and premature scientific conclusions led to ineffective public health measures, care home deaths, and lax vaccination policies. The UK's response fell short of its potential, with a death toll approaching 200,000, due to a lack of evidence-based decision-making.
A new study finds that COVID-19 orphanhood is significantly higher in poorer countries due to pre-existing health and vaccine coverage inequity. The risk is driven by factors like poverty prevalence, lower GDP per capita, and non-communicable diseases.
A global study reveals that COVID-19 has led to a significant increase in orphaned children worldwide. The analysis, conducted by researchers at Australian National University, found that fertility rates, poverty, vaccine coverage, and disease prevalence contribute to the risk of children losing one or both parents during the pandemic.
Researchers at Indian Institute of Science create a novel virus-like particle (VLP) to safely study SARS-CoV-2 mutations and trigger an immune response. The VLP is stable, can attach to host cells, and elicit antibodies that neutralize the live virus.
Researchers have found that human antibodies can incorporate foreign genetic material from the mitochondria and ends of chromosomes, leading to increased immune diversity. This discovery challenges the long-held assumption that antibody diversity results solely from gene mutations.
Researchers developed a DNA vaccine containing multiple parts of the virus, including ones that don't mutate as frequently. The vaccine protected mice against serious infection from the beta variant and activated immune cells recognizing the coronavirus found in bats.
Researchers at Texas Biomed have developed a modified tuberculosis vaccine that can treat non-muscle invasive bladder cancer without strong side effects. The delipidated vaccine triggers well-regulated immune responses and reduces inflammation, making it more effective than traditional treatments.
Researchers developed a new quantitative RT-qPCR assay to detect and quantify the Omicron variant of SARS-CoV-2 in wastewater. The assay revealed that Omicron displaced Delta as the dominant variant within just 3 weeks in an Italian population.
A recent study found that COVID-19 infection significantly increases the risk of myocarditis compared to vaccination, with a 11-fold higher risk in unvaccinated individuals. The study analyzed nearly 43 million people in England and found that COVID-19 vaccine-associated myocarditis is rare.
Researchers developed a broadly neutralizing antibody that neutralized all currently known SARS-CoV-2 variants, including Omicron strains. The antibody works differently from existing antibodies and prevents the virus from fusing with host cells.
Researchers have developed a new way to deliver vaccines through mucosal tissues in the nose, generating strong immune responses in mice and non-human primates. The technology bypasses traditional barriers to delivery by engineering antigens to bind onto albumin, allowing them to effectively target immune tissues.
A recent study suggests that the BCG vaccine is effective in preventing tuberculosis (TB) in children under 5 years old. However, adolescents and adults may require additional protection to maintain immunity beyond childhood. The researchers emphasize the need for booster vaccinations and new TB vaccines to supplement the BCG vaccine.
A new hydrogel-based platform increases vaccine thermal stability, enabling distribution in diverse regions without strict temperature control. The technology has the potential to reduce economic costs and health risks associated with cold chain logistics.
A new vaccine formulation has protected newborn mice against respiratory syncytial virus (RSV) and evoked strong responses in human immune cells. The vaccine uses an adjuvant combination that stimulates type 1 T-helper responses, which are hard to stimulate in newborns but are needed for a strong defense against viral pathogens.
The new tuberculosis vaccine candidate VPM1002 shows its safety and efficacy in a study of HIV-exposed and non-HIV-exposed newborns. The vaccine has fewer side effects compared to the existing BCG vaccine, and elicits a similar immune response.
The National Institutes of Health has updated its Strategic Plan to Cure Hepatitis B, focusing on developing a cure and improving vaccination, screening, and follow-up care strategies. The revised plan aligns with the Department of Health and Human Services' Viral Hepatitis National Strategic Plan.
CoVaRR-Net is investing $6.9 million in 15 research projects focused on understanding Omicron subvariants and finding solutions to curb their spread. The studies will explore various aspects of variants, including viral transmission between animals and people, new variant mutations, and the impact of social factors on Indigenous Peoples.
Researchers create a modified live attenuated mumps virus for delivery, showing it induces stronger immune responses and provides superior protection against SARS-CoV-2. The new vaccine candidate uses a prefusion version of the spike protein and offers potential to enhance MMR childhood vaccine.
Researchers develop technique to control pH at microsites, enabling high-throughput biomolecular synthesis and enzymatic DNA synthesis. This allows for increased experimental throughput and speeding up processes in DNA synthesis.
A recent study found higher antibody titers after the third and fourth Pfizer-BioNTech vaccine doses in individuals aged 60 or older. This population is at high risk of severe SARS-CoV-2 disease, making timely vaccination crucial.
The Novavax COVID-19 vaccine has been recommended by the CDC for primary series use in US adults ages 18+, following FDA authorization. The vaccine demonstrates 90.4% effectiveness in preventing symptomatic COVID-19 and 100% effectiveness against moderate-to-severe disease. NIH and BARDA supported its development, with NIAID scientists...
Researchers developed a new blood test that can indicate cellular immunity to SARS-CoV-2 within 48 hours. The test distinguishes between post-infection and post-vaccination immunity, enabling quick diagnosis for patients unable to produce antibodies. Long-lasting T-cell responses may protect against severe disease in re-infections.
Researchers at the University of Maryland School of Medicine have developed a new method to test malaria vaccines that mimics natural exposure, increasing efficiency and accuracy. The study found the vaccine to be effective in both controlled clinical settings and in the field, with promising results for future mass vaccination programs.
A new recombinant VSV-vectored vaccine developed at UTMB provides rapid protection against lethal Lassa fever, a pathogen causing severe symptoms and high mortality rates. The vaccine was found to be effective against different strains of the virus, critical for outbreak scenarios.
MU researchers have identified specific mutations in the Omicron variant's spike protein that help it evade existing antibodies from vaccines or previous COVID-19 infections. These findings can inform developers of COVID-19 treatments and vaccines, which may need to target different parts of the virus to produce effective outcomes.
Researchers analyze delta variant's biophysical characteristics, revealing unique traits that evade neutralizing antibodies and contribute to severe symptoms. The study sheds light on why vaccinated individuals can still contract the virus and why delta variant hospitalizations are higher than other variants.
The International Vaccine Institute (IVI) has launched a two-week training course for biologics development and manufacturing, targeting low- and middle-income countries. The program aims to enhance local production of vaccines and biologics in LMICs to address vaccine inequity and global pandemic preparedness.
Researchers have created a new mouse model that mimics brain damage caused by severe RVFV infection, enabling the study of disease mechanisms and high-throughput testing of next-generation drugs. This breakthrough has significant implications for developing therapies and vaccines for this devastating virus.
MIT researchers create microparticles that release their payload at different times, enabling self-boosting vaccines. The particles degrade over time and break down once released, allowing for potential use in regions with limited access to medical care.